Published in Volume
119, Issue 10 (October 1, 2009)
J Clin Invest. 2009;119(10):2858–2859.
doi:10.1172/JCI40996.
Copyright © 2009, American Society for Clinical
Investigation. Published under the Creative Commons Attribution-No Derivative Works 3.0
License (United States)
Personal Perspective
Reflections on health care
Laurie H. Glimcher
Harvard Medical School, Boston, Massachusetts, USA. E-mail:
lglimche@hsph.harvard.edu.
First published September 10, 2009
What do we need? Not what we have: a health care system whose costs are
spiraling out of control, that fails to provide care for almost 50 million Americans, and
that ranks far from the top in terms of infant mortality and adequate health care for our
adult population. Ideally, we need a single-payer, universal health care structure. To
paraphrase Ted Kennedy, why shouldn’t all Americans have access to the kind of
health care that is offered to our congressmen and senators? Failing that, health insurance
companies should go away or agree to compete on an equal footing with government-sponsored
health care in a truly free market economy.
Built into that system, though, must be the recognition that we cannot afford to spend such
a large proportion of our health care dollars on the final few months of life. It is
agonizing to watch hundreds of thousands of dollars being spent on ICU care for an elderly,
desperately ill patient who, if he/she could voice an opinion, would ask, in contrast to
Dylan Thomas’s poem, to be allowed to “go gentle into that good
night.” It is a form of abuse to insist on intervention when it is not wanted
and not justified. Those dollars need to go into preventive medicine, drug benefits, and
social programs that teach healthy living skills to avoid chronic, preventable diseases
like obesity, diabetes, and smoking-related lung cancer, not into respirator care for a
96-year-old man with aspiration-induced pneumonia who has begged to be allowed to die in
peace. What happened to the old saying that pneumonia is an old man’s best
friend? The availability of sophisticated technologies doesn’t mandate their
use. Hard choices do need to be made — is an expensive biological therapeutic
that may at best extend a life for six to eight weeks warranted for any patient when those
dollars could instead be spent on well-baby clinic visits? The answer may be yes when the
patient involved is a 40-year-old mother of three with breast cancer, but no when it is an
84-year-old man with metastatic prostate cancer. Who should make those decisions? The
doctors, the patient, the family, and, if necessary, an institutional review board. Common
sense should not be underrated. These issues do not translate into “death
panels”; they speak to reality and to fair play — and to dignity at
the end of life.
The public perception of medicine and doctors as white knights who are not allowed to fail
must also be taken out of the closet, shaken down, dusted off, and revised. Since when did
we believe that life is without risk? The reality is that any procedure, any drug is always
a risk/benefit proposition. Those risks should be made utterly transparent and abundantly
clear. And the inevitable disappointments that ensue when a drug has unfortunate side
effects or a procedure doesn’t go as hoped for should not translate into
medical malpractice suits. That way leads to unnecessary tests and procedures that lead to
spiraling medical care costs. My elder son, a surgical resident at Massachusetts General
Hospital, sees the waste every day. Talk to any doctor and they will tell you they are
forced to order expensive tests solely to protect themselves against malpractice suits.
For goodness’ sakes, let’s give President Obama’s plans
a chance. Are they perfect? No. Are they visionary and courageous? Yes. Get on board,
Republicans and Blue Dog Democrats, because we are headed for disaster with the status
quo.
Footnotes
Conflict of interest: Laurie H. Glimcher is on the Board of Directors of the Bristol-Myers Squibb Pharmaceutical Corporation.